Table 1.
Patient characteristics and endoscopic ultrasound-guided celiac plexus neurolysis -related data
| Phenol | Ethanol | P value | |
| Number of patients | 6 | 16 | |
| Age (yr) [median (range)] | 63 (52-74) | 71 (47-83) | 0.396 |
| Gender (n) [male/female] | 2/4 | 7/9 | 1 |
| Primary site (n) | 1 | ||
| Pancreas/other | 5/1 | 12/4 | |
| Treatment (n) | 0.090 | ||
| CRT/CT/NT | 2/3/1 | 0/11/5 | |
| Direct invasion of celiac plexus (n) | 1 | 7 | 0.350 |
| NRS before CPN [median (range)] | 5.0 (4-7) | 5.5 (4-8) | 0.472 |
| History of narcotic use (n) | 1 | 11 | 0.056 |
| EUS-CPN technique | 0.330 | ||
| Central/CGN | 3/3 | 4/12 | |
| Total amount of neurolytic agent (mL) [median (range)] | 18.0 (13-20) | 13.0 (3.5-20) | 0.085 |
EUS-CPN: Endoscopic ultrasound-guided celiac plexus neurolysis; NRS: Numeric Rating Scale; CRT: Chemoradiotherapy; CT: Chemotherapy; NT: No therapy; CGN: Celiac ganglia neurolysis.